[
  {
    "ts": null,
    "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=57323be3684b4f892853806c518e642b90d6997565f95a5839d2085ed7014801",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856891,
      "headline": "Earnings live: Amazon stock soars, Apple CEO predicts 'best-ever' holiday quarter, Reddit and Coinbase rise",
      "id": 137274982,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=57323be3684b4f892853806c518e642b90d6997565f95a5839d2085ed7014801"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
    "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
    "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856547,
      "headline": "Stocks to Watch Thursday Recap: Eli Lilly, Metsera, Navan, Chipotle",
      "id": 137271937,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.",
      "url": "https://finnhub.io/api/news?id=4bbf27c2793dff14c063655a65d34b638856f58305d8d7e6c5dd644e29ec3b57"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co Inc (MRK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges",
    "summary": "Merck & Co Inc (MRK) reports a 4% revenue increase driven by Keytruda's demand, while facing headwinds in Gardasil sales and competitive pressures.",
    "url": "https://finnhub.io/api/news?id=32e7960852c0f2bc8cd5f163e1dde7a4776d4c3e8becdbe9bc4977256fe9ac25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761856288,
      "headline": "Merck & Co Inc (MRK) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges",
      "id": 137275071,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co Inc (MRK) reports a 4% revenue increase driven by Keytruda's demand, while facing headwinds in Gardasil sales and competitive pressures.",
      "url": "https://finnhub.io/api/news?id=32e7960852c0f2bc8cd5f163e1dde7a4776d4c3e8becdbe9bc4977256fe9ac25"
    }
  },
  {
    "ts": null,
    "headline": "Moderna stock soars after report of potential buyout talks",
    "summary": "Investing.com -- Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about \"a deal of significant scope,\" which could include a potential acquisition.",
    "url": "https://finnhub.io/api/news?id=1867a86bc3ab33bcba6cfbce52decf14f1c3807ec8ec25e6f28d1f7803c58aa5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844956,
      "headline": "Moderna stock soars after report of potential buyout talks",
      "id": 137268786,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com -- Moderna (NASDAQ:MRNA) stock surged as much as 12% Thursday following a STAT News report that the COVID-19 vaccine maker has been in discussions with at least one large pharmaceutical company about \"a deal of significant scope,\" which could include a potential acquisition.",
      "url": "https://finnhub.io/api/news?id=1867a86bc3ab33bcba6cfbce52decf14f1c3807ec8ec25e6f28d1f7803c58aa5"
    }
  },
  {
    "ts": null,
    "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
    "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
    "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761844560,
      "headline": "Bladder Cancer Market - Global and Regional Analysis and Forecast (2025-2035) Featuring Merck & Co., Bristol Myers Squibb, Astellas Pharma, AstraZeneca, and Johnson & Johnson",
      "id": 137268736,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The \"Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering.The market's growth is primarily driven by the rising incidence of bladder cancer, advancements in diagnostic technologies, and the growing availability of innovative treatments such as immunotherapy and targeted therapies for bladder cancer management.Market Lifecycle StageThe market is currently in the expan",
      "url": "https://finnhub.io/api/news?id=9a0326b70bd21d4034bf6fd8947f86a65c4eb02d4b5a41850de931e9a4df3c99"
    }
  },
  {
    "ts": null,
    "headline": "MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down",
    "summary": "Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.",
    "url": "https://finnhub.io/api/news?id=1f4f546e5e058742721d3e7f9070c26c4b21aada318d119f5e5bb5bbb5f96b31",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761842460,
      "headline": "MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down",
      "id": 137268788,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck tops Q3 earnings and revenue estimates on strong oncology, new drugs and animal health sales, while narrowing its 2025 revenue outlook.",
      "url": "https://finnhub.io/api/news?id=1f4f546e5e058742721d3e7f9070c26c4b21aada318d119f5e5bb5bbb5f96b31"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
    "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
    "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761827474,
      "headline": "Stocks to Watch Thursday: Eli Lilly, Metsera, Navan, Microsoft",
      "id": 137266379,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "↘️ Meta Platforms (META): The social-media company said it would “aggressively” raise spending to stay competitive in the artificial-intelligence arms race. That sent shares down more than 8.5% in premarket trading.",
      "url": "https://finnhub.io/api/news?id=f2fc75eb0410e65261398c78593125e759a0a1f2e24e638b65b11b190bcd491a"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock Falls. Sales of Key Products Missed Estimates.",
    "summary": "Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.",
    "url": "https://finnhub.io/api/news?id=cc3aff2daf81fda44f2ae6033144e0d204d3299a3fb293d8d522281a96b7a03f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832140,
      "headline": "Merck Stock Falls. Sales of Key Products Missed Estimates.",
      "id": 137268790,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.",
      "url": "https://finnhub.io/api/news?id=cc3aff2daf81fda44f2ae6033144e0d204d3299a3fb293d8d522281a96b7a03f"
    }
  },
  {
    "ts": null,
    "headline": "Merck’s (NYSE:MRK) Q3 Sales Top Estimates",
    "summary": "Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be around $64.75 billion, close to analysts’ estimates. Its non-GAAP profit of $2.58 per share was 9.9% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=640948511e9fe4bc7cb407509fde1de56e36b3fd601915fa38313c0de2a9dcd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831968,
      "headline": "Merck’s (NYSE:MRK) Q3 Sales Top Estimates",
      "id": 137268791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 3.7% year on year to $17.28 billion. The company expects the full year’s revenue to be around $64.75 billion, close to analysts’ estimates. Its non-GAAP profit of $2.58 per share was 9.9% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=640948511e9fe4bc7cb407509fde1de56e36b3fd601915fa38313c0de2a9dcd5"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
    "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
    "url": "https://finnhub.io/api/news?id=2d2281d2aeeb41d23785308c25ba1f8b1e19a992391020c245ed5672aecfeb81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831826,
      "headline": "Dow Jones Stock Merck Tops Expectations, But Gardasil Challenges Remain",
      "id": 137266602,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Dow Jones stock Merck topped third-quarter forecasts on Thursday, but shares skidded as its challenges with vaccine Gardasil continued.",
      "url": "https://finnhub.io/api/news?id=2d2281d2aeeb41d23785308c25ba1f8b1e19a992391020c245ed5672aecfeb81"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript",
    "summary": "Merck & Co., Inc. (MRK) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDTCompany ParticipantsPeter Dannenbaum - Vice President of Investor...",
    "url": "https://finnhub.io/api/news?id=882af4e58b798f1dc9bd5e1d6e7900e88e30f6fd6e11c07f0f736f4ab2573222",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831384,
      "headline": "Merck & Co., Inc. (MRK) Q3 2025 Earnings Call Transcript",
      "id": 137268264,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) Q3 2025 Earnings Call October 30, 2025 9:00 AM EDTCompany ParticipantsPeter Dannenbaum - Vice President of Investor...",
      "url": "https://finnhub.io/api/news?id=882af4e58b798f1dc9bd5e1d6e7900e88e30f6fd6e11c07f0f736f4ab2573222"
    }
  },
  {
    "ts": null,
    "headline": "My Top 10 High-Yield Picks For November 2025: One Yields 9%+",
    "summary": "These top high-yield dividend stocks provide income and growth. Learn how diversified picks like CVX, VZ, MO & ARCC can boost your portfolio.",
    "url": "https://finnhub.io/api/news?id=4cf18d02d9223cc08fd54110f96b4d4a127794abbdac2cc5f945fe2901caa4dc",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831217,
      "headline": "My Top 10 High-Yield Picks For November 2025: One Yields 9%+",
      "id": 137268228,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/458260449/image_458260449.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "These top high-yield dividend stocks provide income and growth. Learn how diversified picks like CVX, VZ, MO & ARCC can boost your portfolio.",
      "url": "https://finnhub.io/api/news?id=4cf18d02d9223cc08fd54110f96b4d4a127794abbdac2cc5f945fe2901caa4dc"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say",
    "summary": "The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
    "url": "https://finnhub.io/api/news?id=afd2d8cc68aebaa61bfe73ec41e70d6b1dd3c92edba2e0624f405425d06e957e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761831012,
      "headline": "Merck (MRK) Reports Q3 Earnings: What Key Metrics Have to Say",
      "id": 137268792,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.",
      "url": "https://finnhub.io/api/news?id=afd2d8cc68aebaa61bfe73ec41e70d6b1dd3c92edba2e0624f405425d06e957e"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Flat to Higher Premarket Thursday",
    "summary": "Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)",
    "url": "https://finnhub.io/api/news?id=80d347c7c478d56c2cbb9d2b3cb8d907f171b2486e888e8310ac2c9c5cdbdf28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830732,
      "headline": "Sector Update: Health Care Stocks Flat to Higher Premarket Thursday",
      "id": 137266481,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB)",
      "url": "https://finnhub.io/api/news?id=80d347c7c478d56c2cbb9d2b3cb8d907f171b2486e888e8310ac2c9c5cdbdf28"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
    "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
    "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761830730,
      "headline": "Novo Nordisk's bid for Metsera, Eli Lilly boosts revenue outlook",
      "id": 137266482,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Novo Nordisk's (NVO) bidding war with Pfizer (PFE) over who acquires Metsera (MTSR), Merck (MRK) cutting the higher end of its sales guidance, and Eli Lilly (LLY) raising its full-year revenue forecast after topping third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.",
      "url": "https://finnhub.io/api/news?id=60f388828ad12dc7bb084b4b48253c813cc0b11a8bb2ae6b33b6fa57b259f68c"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Falls After Trump-Xi Talks; Meta Plunges On Cost Worries (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped Thursday after Trump-Xi talks. Meta stock plunged on earnings.",
    "url": "https://finnhub.io/api/news?id=f513d24ae33dcd2622e4b69e03bee9048aa3955978b3eb5667656dd19e49d9f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761832427,
      "headline": "Stock Market Today: Dow Falls After Trump-Xi Talks; Meta Plunges On Cost Worries (Live Coverage)",
      "id": 137266328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index dropped Thursday after Trump-Xi talks. Meta stock plunged on earnings.",
      "url": "https://finnhub.io/api/news?id=f513d24ae33dcd2622e4b69e03bee9048aa3955978b3eb5667656dd19e49d9f4"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet jumps as Big Tech earnings pour in",
    "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=1fa07bf780600b90af7fc3d428f6241095afe7f43e3bc0c498059d8281304daf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761826759,
      "headline": "Earnings live: Meta stock tumbles, Microsoft slides, and Alphabet jumps as Big Tech earnings pour in",
      "id": 137266361,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=1fa07bf780600b90af7fc3d428f6241095afe7f43e3bc0c498059d8281304daf"
    }
  },
  {
    "ts": null,
    "headline": "Merck third quarter sales beat expectations while net income leaps 83%",
    "summary": "Merck third quarter sales beat expectations while net income leaps 83%",
    "url": "https://finnhub.io/api/news?id=e16b0c9f36e07b792570a3f2fc1e6f7887b5003f4ec7f69a1925dd41c54abb20",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761825326,
      "headline": "Merck third quarter sales beat expectations while net income leaps 83%",
      "id": 137266012,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e16b0c9f36e07b792570a3f2fc1e6f7887b5003f4ec7f69a1925dd41c54abb20"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Fall Pre-Bell as Investors Assess Trump-Xi Meeting Outcome; Powell Casts Doubt on December Rate Cut",
    "summary": "US equity markets were tracking in the red before the opening bell Thursday as traders digest the ou",
    "url": "https://finnhub.io/api/news?id=ad2da0022375fb8fcdb02d4e92e31936f6bc18878e038e9dce39b86b3c0959e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824830,
      "headline": "Stocks Fall Pre-Bell as Investors Assess Trump-Xi Meeting Outcome; Powell Casts Doubt on December Rate Cut",
      "id": 137266363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity markets were tracking in the red before the opening bell Thursday as traders digest the ou",
      "url": "https://finnhub.io/api/news?id=ad2da0022375fb8fcdb02d4e92e31936f6bc18878e038e9dce39b86b3c0959e0"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Q3 Earnings and Revenues Beat Estimates",
    "summary": "Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d916535191d746202d0a1370720c01fe53a259a423202251568648e1144468a0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761824702,
      "headline": "Merck (MRK) Q3 Earnings and Revenues Beat Estimates",
      "id": 137266608,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) delivered earnings and revenue surprises of +9.32% and +1.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d916535191d746202d0a1370720c01fe53a259a423202251568648e1144468a0"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
    "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
    "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761823920,
      "headline": "Bristol Myers Squibb Stock Rises After Solid Earnings. But These Problems Remain.",
      "id": 137266539,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Bristol Myers Squibb  hiked its full-year guidance on the back of a strong third quarter underlined by demand for drugs within its growth portfolio.  The pharmaceutical giant raised its full-year revenue guidance to a range of $47.5 billion to $48 billion from a previous forecast of $46.5 billion to $47.5 billion.  Bristol Myers now sees adjusted earnings between $6.40 and $6.60 a share, versus a previous range of $6.35 to $6.65 a share.",
      "url": "https://finnhub.io/api/news?id=110f0830813ac85201f26d77bc43a593a1a6c7ab03256a56326c24a669b16259"
    }
  },
  {
    "ts": null,
    "headline": "Lilly hikes revenue forecasts on booming obesity drug sales",
    "summary": "Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug.",
    "url": "https://finnhub.io/api/news?id=286618aa820b6bdb1105d7c4a380f615f8fe8e9755d08d5cb4368560e2c88e95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822720,
      "headline": "Lilly hikes revenue forecasts on booming obesity drug sales",
      "id": 137268793,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug.",
      "url": "https://finnhub.io/api/news?id=286618aa820b6bdb1105d7c4a380f615f8fe8e9755d08d5cb4368560e2c88e95"
    }
  },
  {
    "ts": null,
    "headline": "Merck narrows full-year sales guidance",
    "summary": "Investing.com - Merck has narrowed its full-year sales forecast, as a boost from an amended collaboration agreement with peer AstraZeneca and lower tariff costs was mitigated by costs connected to its purchase of Verona Pharma.",
    "url": "https://finnhub.io/api/news?id=27742642c27fd31712ba4db25eeb691585cc50621087a4db3bde8f9930df6eb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761822456,
      "headline": "Merck narrows full-year sales guidance",
      "id": 137266610,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Investing.com - Merck has narrowed its full-year sales forecast, as a boost from an amended collaboration agreement with peer AstraZeneca and lower tariff costs was mitigated by costs connected to its purchase of Verona Pharma.",
      "url": "https://finnhub.io/api/news?id=27742642c27fd31712ba4db25eeb691585cc50621087a4db3bde8f9930df6eb4"
    }
  },
  {
    "ts": null,
    "headline": "Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time.",
    "summary": "Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.",
    "url": "https://finnhub.io/api/news?id=90c6977749d23a5ea38003069152666c87d47a4333b920370392d28c8206c9d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821460,
      "headline": "Merck Stock Falls After Earnings. Keytruda Sales Top $8 Billion for First Time.",
      "id": 137266611,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer drug.",
      "url": "https://finnhub.io/api/news?id=90c6977749d23a5ea38003069152666c87d47a4333b920370392d28c8206c9d6"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Q3 Earnings Snapshot",
    "summary": "RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Thursday reported third-quarter earnings of $5.79 billion. The Rahway, New Jersey-based company said it had net income of $2.32 per share. Earnings, adjusted for one-time gains and costs, came to $2.58 per share.",
    "url": "https://finnhub.io/api/news?id=441581c8fbab6fd48c92887a69611f2ed8494bcb20908c4075cc3059fd1bef4b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761821312,
      "headline": "Merck: Q3 Earnings Snapshot",
      "id": 137266612,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Thursday reported third-quarter earnings of $5.79 billion. The Rahway, New Jersey-based company said it had net income of $2.32 per share. Earnings, adjusted for one-time gains and costs, came to $2.58 per share.",
      "url": "https://finnhub.io/api/news?id=441581c8fbab6fd48c92887a69611f2ed8494bcb20908c4075cc3059fd1bef4b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Profit Rises on Strong Keytruda Demand",
    "summary": "Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.",
    "url": "https://finnhub.io/api/news?id=0b6f31b631729bec43c0f05d4b8fd862d1c396d98f4f3ac27862c26377364511",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761820860,
      "headline": "Merck Profit Rises on Strong Keytruda Demand",
      "id": 137266613,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck reported higher third-quarter profit and boosted its full-year outlook, as demand for its flagship Keytruda cancer drug continues to rise.",
      "url": "https://finnhub.io/api/news?id=0b6f31b631729bec43c0f05d4b8fd862d1c396d98f4f3ac27862c26377364511"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
    "summary": "RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
    "url": "https://finnhub.io/api/news?id=35d1a550acc03b16b9fabeff7e6485c646a32923ef0a177b185a476b0e35f10f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761820200,
      "headline": "Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
      "id": 137266540,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 30, 2025--Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results",
      "url": "https://finnhub.io/api/news?id=35d1a550acc03b16b9fabeff7e6485c646a32923ef0a177b185a476b0e35f10f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. 2025 Q3 - Results - Earnings Call Presentation",
    "summary": "2025-10-30. The following slide deck was published by Merck & Co., Inc.",
    "url": "https://finnhub.io/api/news?id=f6068c420fbdb4f852273441ad0045a4ea4b0494db8a5e04ef272ba995b73c11",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761818519,
      "headline": "Merck & Co., Inc. 2025 Q3 - Results - Earnings Call Presentation",
      "id": 137266834,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "2025-10-30. The following slide deck was published by Merck & Co., Inc.",
      "url": "https://finnhub.io/api/news?id=f6068c420fbdb4f852273441ad0045a4ea4b0494db8a5e04ef272ba995b73c11"
    }
  },
  {
    "ts": null,
    "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
    "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
    "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761816041,
      "headline": "Merck: Wall Street Surprised By Q3 Strength, Keytruda Sales Surge",
      "id": 137266210,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1389349379/image_1389349379.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on MRK stock.",
      "url": "https://finnhub.io/api/news?id=781901023f2d2f6d302e52852d90fc1f00f9272f1f80893967bd0459c3622dc9"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN)",
    "summary": "We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon & Co. (NYSE:OGN) is a women’s health company that provides fertility and contraceptive products. It’s been caught in a wave of controversy lately after CEO Kevin Ali […]",
    "url": "https://finnhub.io/api/news?id=63e892fd64b54eed0f9f46d47ff7ae2936e09c90902d534609e8e228fbb6cdbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761814597,
      "headline": "Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN)",
      "id": 137266615,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We recently published 11 Stocks Jim Cramer Discussed, Including A Potential “Worst Stock Ever”. Organon & Co. (NYSE:OGN) is one of the stocks Jim Cramer recently discussed. Organon & Co. (NYSE:OGN) is a women’s health company that provides fertility and contraceptive products. It’s been caught in a wave of controversy lately after CEO Kevin Ali […]",
      "url": "https://finnhub.io/api/news?id=63e892fd64b54eed0f9f46d47ff7ae2936e09c90902d534609e8e228fbb6cdbe"
    }
  }
]